中国实用儿科杂志 ›› 2026, Vol. 41 ›› Issue (8): 654-657.DOI: 10.19538/j.ek2026080608

• 专题笔谈 • 上一篇    下一篇

肿瘤坏死因子抑制剂在儿童风湿免疫性疾病的应用

  

  1. 青岛大学附属医院儿童肾脏风湿免疫科,山东  青岛  266003
  • 出版日期:2026-08-06 发布日期:2026-09-17
  • 通讯作者: 张秋业,电子信箱:qyzh9816@163.com

Clinical application of tumor necrosis factor inhibitors in pediatric rheumatic and immune diseases

  1. Department of Pediatric Nephrology and Rheumatology,the Affiliated Hospital of Qingdao University,Qingdao  266003,China
  • Online:2026-08-06 Published:2026-09-17

摘要: 肿瘤坏死因子抑制剂(TNFi)是治疗儿童风湿免疫性疾病的重要生物制剂。肿瘤坏死因子(TNF)-α作为关键炎症细胞因子,在多种自身免疫性疾病中过度表达,TNFi 通过特异性阻断TNF-α的生物学活性发挥治疗作用。临床常用的TNFi 主要包括受体融合蛋白类(依那西普)和单克隆抗体类(英夫利西单抗、阿达木单抗等)。TNFi 在成人的获批适应证包括类风湿性关节炎、强直性脊柱炎等;在儿童的获批适应证主要包括多关节型幼年特发性关节炎,以及非感染性葡萄膜炎等。此外,TNFi 在腺苷脱氨酶2 缺陷病、白塞病等多种难治性风湿性疾病中也有较多用药经验。儿童应用TNFi 总体安全性良好,治疗前应筛查潜伏的结核和乙肝感染,并定期监测疗效和不良反应。

关键词: font-family:", font-size:17px, background-color:#FFFFFF, ">肿瘤坏死因子抑制剂, 风湿免疫性疾病, 儿童, 疾病治疗

Abstract: Tumor necrosis factor inhibitors(TNFi)are an important class of biological agents for the management of pediatric rheumatic and immune diseases.TNF-α is a key inflammatory cytokine overexpressed in various autoimmune conditions. TNFi play their therapeutic roles by specifically blocking the biological activity of TNF-α.Two main categories are used clinically:receptor fusion proteins(etanercept)and monoclonal antibodies(infliximab and adalimumab).Approved adult indications of TNFi include rheumatoid arthritis and ankylosing spondylitis;approved pediatric indications include polyarticular juvenile idiopathic arthritis and non-infectious uveitis.In addition,TNFi have also shown clinical utility in refractory rheumatic diseases such as adenosine deaminase 2 deficiency and Behçet’s disease.The overall safety profile is favorable in children.Screening for latent tuberculosis and hepatitis B before treatment initiation,along with regular monitoring of efficacy and adverse events,is recommended. 

Key words: tumor necrosis factor inhibitors, rheumatic and immune diseases, child, treatment for diseases